Pneumology and Critical Care Medicine, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany
Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
BMJ Open. 2024 May 28;14(5):e080518. doi: 10.1136/bmjopen-2023-080518.
Application of vapour ablation as a novel approach to lung volume reduction has positive effects in patients with severe emphysema. The BENTO study is a randomised, controlled, open, multicentre trial, to assess the effects of bronchoscopic thermal vapour ablation (BTVA) in the German healthcare system.
Patients with bilateral heterogeneous emphysema of the upper lobes in Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 3/4 will be enrolled in this trial and will receive either standard medical management alone (according to GOLD guidelines) or BTVA treatment with the InterVapor system together with standard medical management. Patients will be randomised in a 2:1 ratio (treatment group:control group). A total of 224 patients will be enrolled at 15 study sites. The primary endpoint is the change in patient-reported disease-specific quality of life, as measured by the St George's Respiratory Questionnaire for chronic obstructive pulmonary disease patients between randomisation and the 9-month follow-up visit. Secondary endpoints include adverse events, mortality, vital status, changes in lung function parameters, exercise capacity and other efficacy measures at 3, 9 and 12 months.The BENTO trial was commissioned by the German Federal Joint Committee, to demonstrate that this approach is an efficient and safe treatment option in the German healthcare system.
The protocol has been approved by the lead ethics committee in Germany (Ethics Committee of the Medical Faculty of Heidelberg) and until present also by the following ethics committees: Ethics Committee of the Medical Faculty of Duisburg-Essen, Ethics Committee of the Medical Faculty of Martin-Luther-University Halle-Wittenberg, Ethics Committee of the State Medical Association of Hessen, Ethics Commission of the State Office for Health and Social Affairs of the State of Berlin, Ethics Committee of the Medical Faculty of Greifswald. The results will be published in a peer-reviewed journal.
NCT05717192.
将蒸汽消融作为一种治疗严重肺气肿的新方法,已被证明对患者具有积极影响。BENTO 研究是一项随机、对照、开放、多中心试验,旨在评估支气管热蒸汽消融(BTVA)在德国医疗体系中的效果。
本试验将招募双侧上叶不均匀肺气肿的 GOLD 3/4 期患者,他们将接受标准医疗管理(根据 GOLD 指南)或使用 InterVapor 系统的 BTVA 治疗联合标准医疗管理。患者将按照 2:1 的比例(治疗组:对照组)进行随机分组。共 224 例患者将在 15 个研究中心入组。主要终点是通过圣乔治呼吸问卷(chronic obstructive pulmonary disease patients)评估患者报告的疾病特异性生活质量在随机分组和 9 个月随访期间的变化。次要终点包括不良事件、死亡率、生存状态、肺功能参数变化、运动能力和其他在 3、9 和 12 个月时的疗效指标。BENTO 试验由德国联邦联合委员会委托进行,旨在证明这种方法是德国医疗体系中一种有效且安全的治疗选择。
该方案已获得德国主要伦理委员会(海德堡医学伦理委员会)的批准,迄今为止,还获得了以下伦理委员会的批准:杜伊斯堡-埃森医学伦理委员会、马丁路德-哈勒-维滕贝格医学伦理委员会、黑森州医学协会伦理委员会、柏林州卫生和社会事务州办公室伦理委员会、格赖夫斯瓦尔德医学伦理委员会。研究结果将发表在同行评议的期刊上。
NCT05717192。